Ouro Medicines, Inc.

Founded in 2025 and based in California, US, Ouro Medicines, Inc. specializes in creating therapeutics for immune-mediated diseases. In March 2026, Gilead Sciences, Inc. a portfolio company of Abingworth, agreed to fully acquire Ouro Medicines, Inc.

from UPMC Enterprises, LongRiver Investments, Monograph Capital, Boyu Capital, GlaxoSmithKline, Norwest Venture Partners, TPG, and New Enterprise Associates for USD 1. 68 billion. Upon completion of the transaction, the company will receive an additional payment of up to USD 500 million in contingent milestone payments. Ouro Medicines specializes in developing therapeutics aimed at resetting the immune system, focusing primarily on chronic immune-mediated diseases.

The company’s core product is the lead therapeutic candidate, OM336, which utilizes T cell engagers (TCEs) to deplete proinflammatory cells. TCEs serve as an off-the-shelf therapeutic modality designed to induce an immunological 'reset,' potentially allowing for durable remissions without ongoing immunosuppression. Additionally, Ouro Medicines is advancing several discovery programs targeting unique subsets of B cells to facilitate longer remissions for certain diseases. The company operates a revenue model primarily driven by partnerships and collaborations with biopharmaceutical companies for the development and commercialization of its therapeutics.

Revenue generation is expected through licensing agreements and milestone payments associated with their lead candidate, OM336, and other products in their pipeline. The 2026 acquisition enables Ouro Medicines, Inc. to advance the clinical development of its BCMAxCD3 T‑cell engager and accelerate its path toward late‑stage studies in autoimmune diseases.